Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Bramlage

Showing results (11-20 of 429) with videos related to

Pageof 43
Sort By:
BMC Pharmacology|October 31, 2008
Bioequivalence study of three ibuprofen formulations after single dose administration in healthy volunteersPeter Bramlage, Adrian Goldis
Journal of Clinical Hypertension (Greenwich, Conn.)|March 4, 2016
Is Azilsartan More Effective in Younger Than in Older Patients? An Explorative Analysis of the Prospective EARLY RegistryRoland E Schmieder, Peter Bramlage,
Vascular Health and Risk Management|January 14, 2012
Office and ambulatory blood pressure control with a fixed-dose combination of candesartan and hydrochlorothiazide in previously uncontrolled hypertensive patients: results of CHILI CU SoonThomas Mengden, Reinhold Hübner, Peter Bramlage
Vascular Health and Risk Management|March 19, 2011
Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T)Gerd Bönner, Bernhard Landers, Peter Bramlage
Clinical Drug Investigation|February 1, 2014
Candesartan cilexetil 32 mg/hydrochlorothiazide 25 mg in unselected patients with high or very high cardiovascular risk: efficacy, safety, and metabolic impactPeter Bramlage, Hartmut Buhck, Claudia Zemmrich
Medizinische Klinik (Munich, Germany : 1983)|January 15, 2009
[Outpatient treatment of deep vein thrombosis with low-molecular-weight heparins. Experience from an open, prospective study in daily practice]Christian Heidenreich, Volker Hohmann, Peter Bramlage
Journal of Clinical Hypertension (Greenwich, Conn.)|February 20, 2018
Fixed-dose vs free-dose combinations for the management of hypertension-An analysis of 81 958 patientsPeter Bramlage, Stefanie Schmidt, Helen Sims
MMW Fortschritte Der Medizin|October 25, 2007
[Cardiometabolic high risk patients with abdominal obesity. Frequency and risk factor profile in primary care]Jürgen Scholze, Wolfgang Lilienthal, Peter Bramlage
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|November 16, 2011
Prevention of venous thromboembolism using enoxaparin in day surgery: results of the SMART noninterventional studySylvia Haas, Volker Hohmann, Peter Bramlage
Thrombosis and Haemostasis|February 23, 2010
Stem cell and progenitor cell therapy in peripheral artery disease. A critical appraisalHolger Lawall, Peter Bramlage, Berthold Amann
Pageof 43

Showing results (11-20 of 429) with videos related to

Sort By:
Pageof 43
BMC Pharmacology|October 31, 2008
Bioequivalence study of three ibuprofen formulations after single dose administration in healthy volunteersPeter Bramlage, Adrian Goldis
Journal of Clinical Hypertension (Greenwich, Conn.)|March 4, 2016
Is Azilsartan More Effective in Younger Than in Older Patients? An Explorative Analysis of the Prospective EARLY RegistryRoland E Schmieder, Peter Bramlage,
Vascular Health and Risk Management|January 14, 2012
Office and ambulatory blood pressure control with a fixed-dose combination of candesartan and hydrochlorothiazide in previously uncontrolled hypertensive patients: results of CHILI CU SoonThomas Mengden, Reinhold Hübner, Peter Bramlage
Vascular Health and Risk Management|March 19, 2011
Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T)Gerd Bönner, Bernhard Landers, Peter Bramlage
Clinical Drug Investigation|February 1, 2014
Candesartan cilexetil 32 mg/hydrochlorothiazide 25 mg in unselected patients with high or very high cardiovascular risk: efficacy, safety, and metabolic impactPeter Bramlage, Hartmut Buhck, Claudia Zemmrich
Medizinische Klinik (Munich, Germany : 1983)|January 15, 2009
[Outpatient treatment of deep vein thrombosis with low-molecular-weight heparins. Experience from an open, prospective study in daily practice]Christian Heidenreich, Volker Hohmann, Peter Bramlage
Journal of Clinical Hypertension (Greenwich, Conn.)|February 20, 2018
Fixed-dose vs free-dose combinations for the management of hypertension-An analysis of 81 958 patientsPeter Bramlage, Stefanie Schmidt, Helen Sims
MMW Fortschritte Der Medizin|October 25, 2007
[Cardiometabolic high risk patients with abdominal obesity. Frequency and risk factor profile in primary care]Jürgen Scholze, Wolfgang Lilienthal, Peter Bramlage
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|November 16, 2011
Prevention of venous thromboembolism using enoxaparin in day surgery: results of the SMART noninterventional studySylvia Haas, Volker Hohmann, Peter Bramlage
Thrombosis and Haemostasis|February 23, 2010
Stem cell and progenitor cell therapy in peripheral artery disease. A critical appraisalHolger Lawall, Peter Bramlage, Berthold Amann
Pageof 43